Work / Animation / A Focus on ALK-positive Non-Small Cell Lung Cancer
In partnership with Wedgewood Communications, XVIVO developed two videos for Takeda Oncology to discuss lung cancer mechanism of disease and treatments.
This animation takes an extensive and detailed look at the sub-populations of patients who have non-small cell lung cancer (NSCLC), which affects about 198,000 new patients in the United States each year.
The animation discussed the variety of possible mutations seen in lung cancer, with a focus on NSCLCs with an ALK mutation. With so many acronyms to be used in the animation, we were challenged to clearly present the lung cancer types and the possible genetic mutations found in the tumor cells.
A Focus on ALK-positive Non-Small Cell Lung Cancer
About 50,000 people in the United States are diagnosed with IPF each year. After diagnosis, the estimated survival is only…
In collaboration with Global Blood Therapeutics, our folks here at XVIVO created this medical animation to illustrate the mechanism of…
XVIVO was approached by the NIH (National Institutes of Health) to help raise awareness of extracellular RNA (exRNA). After working…
VP, Director of Production, JUICE Pharma Advertising
My experience working with XVIVO can be summed up in one word: Confidence. Confidence in the depth of scientific knowledge they contributed, this knowledge only enhanced the end product, was evident as a core competency from our initial discussions even before engaging them for the production, and inspired our team because they were collaborating with a partner who is as dedicated to the science of the story as they are.